Mettler-Toledo International Inc. (MTD) Earnings Call Transcript & Summary

Good afternoon, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at JPMorgan. I am joined by the Mettler-Toledo team up here. As a reminder, these are typically 40-minute sessions. Roughly, the first half will be a prepared presentation followed by roughly 20 minutes of Q&A. And with that, I will pass it off to Patrick.

Thank you, Rachel, and good afternoon everyone here in the room and to those joining us on the webcast. Thank you for being here today. Similar to the past, I'd like to start off by providing an overview of the business, our competitive advantages and update on our growth strategies and why we are well positioned to deliver excellent shareholder returns going forward. Before we get started, please note our disclosure regarding forward-looking statements in this slide. Well, to start off, for those of you who are not familiar with our company, Mettler-Toledo is a global market leader in precision measurement instruments used to laboratory and industrial applications around the world. We generated around $3.8 billion in revenue and a significant majority of our sales are in segments in which we are the global market leader. Our business is very diversified in terms of the products we sell throughout our customers' value chain, the end markets we serve and the geography and the fragmentation and diversity of our business provides significant opportunity for growth and market share expansion. We are well on track for our -- we are well known for our track record of delivering excellent financial results, and we are very much focused on continuing to build on this track record going forward. We do this by leveraging our many competitive advantages, well-developed and proven growth strategies and our unique culture of innovation, collaboration, focused execution and continuous improvement. Over the past couple of years, we have also rolled out the next generation of several corporate programs such as Spinnaker and SternDrive while accelerating our pace of innovation that will help us to continue to deliver our long-term best-in-class financial performance. Now turning to our market exposure. We serve attractive end markets and estimate that about -- that over 70% of our sales are to attractive growth markets of pharma and biopharma, food manufacturers and specialty chemicals. Our business mix has improved over the years through expansion of our portfolio and as our Spinnaker sales and marketing program has become even more sophisticated in guiding our sales teams to the most attractive opportunities we see across these markets. The markets that we target are also increasingly seeking solutions that can increase productivity, ensure compliance with ever more strict regulatory requirements and data integrity as well as higher levels of accuracy and reusability. We have approximately 25 different strategic business units, each representing a major product category. We typically have different competition in each category. The breadth of our products offering means that we can offer a wide range of solutions to help our customers across the entire value chain from research and development, to scale up, quality control and all the way through to production, final inspection at the end of the production line and logistics. The significant diversity of our product offering and our exposure across our customers' entire value chain provides for significant resilience in our financial results, but also excellent growth opportunities. Now let's briefly review our product offering, starting with our laboratory instruments, which represent more than 55% of our total sales. We provide scientists and chemists the most frequently used instruments in biopharma, chemical and food labs for research and development and quality control applications. This slide highlights our laboratory offering that helps customers in R&D labs. These customers require a high degree of precision and flexibility, which we support with pipettes, balances, analytical instruments and automated chemistry solutions. We are well known for our innovation, quality and deep application know-how. Our laboratory instruments are also used -- also very important in QA and QC labs, and we provide these customers approximately 40% of the bench instruments that are typically found in an analytical quality control lab. We continue to expand our portfolio of instruments with automation features, which provide tangible productivity gains and better data management. Software has increasingly become a deciding factor for customers in choosing a supplier for bench top instruments and our LabX instrument control and data management software is unique in its ability to connect the majority of our broad portfolio of instruments in a highly compliant and audit proof manner and can also automate workflows. The last piece of our lab business is process analytics, which is the market leader in continuous in-line monitoring of process control parameters like pH, oxygen, CO2 and pressure sensors as well as ultra pure water applications that are connected to our transmitters. Biopharma is a very important end market for this business along with the chemical industry and semiconductors. This next slide is an overview of several of our industrial products and solutions which represents about 40% of our total sales. The largest portion of industrial is our core industrial business, which represents approximately 25% of our total sales and represents our scales, weigh modules, terminals and software that are used by our customers, for example, to control formulation, filling and dosing in their production process. Here, we provide weighing solutions that facilitate process control for many of the same customers as our lab products, pharma and biopharma, food, specialty chemical and many others, but in their production environment. The mix of this business has shifted over time with approximately 60% of our sales to these more attractive end markets, but our product mix has shifted as well as customers increasingly adopt our automation solutions that integrate seamlessly in their factory automation systems or provide enhanced operator guidance. The other portion of our industrial business is product inspection which represents about 15% of our total sales. In this business, we sell a variety of instruments primarily to packaged food manufacturers, but also to customers in pharma and the cosmetic industry, to help them detect physical contaminants or prevent over and under filling in the -- of their products. This is a critical end-of-line process that ensures brand protection, high quality and increased productivity. In addition to our broad product offering, we have a comprehensive service offering that helps our customers maintain reliable readings from our instruments and maximize uptime in a production environment. Service represents approximately 25% of our total sales and above-average profitability, and it is an important competitive advantage, but also an important growth opportunity that I will expand on later. This slide details our competitive advantages and why we are so confident in our long-term growth perspectives. First, we are the market leader in a significant majority of our businesses, but many of our markets tend to be very diversified and highly fragmented. Our market share on average is only in the range of 25%, and our long history of innovation and strong product portfolio provides ample of room for continued market share expansion. Secondly, A significant majority of our sales are through our own sales force of over 3,000 employees. Our specialist sales force with deep application know-how, and the ability to sell directly to the end user is a strong competitive advantage. Our customer base is also highly diversified, and no one end user is representing more than 1% of our sales. We reached this fragmented and diverse customer base through our internally developed sales and marketing excellence program called Spinnaker that I will provide more detail on in a few moments. We also have a very large installed base of over $16 billion of instruments in the field. This installed base is a source of steady replacement demand and also a large service opportunity and we support this installed base with the largest global service organization of our direct competitors. Our global supply chain and manufacturing presence are enabled by Blue Ocean, our process and system harmonization program. Blue Ocean's harmonized process and single-instance information technology infrastructure provides rich data and business insights as well as significant productivity opportunities. And lastly, we have a unique culture at Mettler-Toledo that is squarely focused on our customers, on innovation, collaboration, continuous improvement and utility. I'd like to say that who we are is why we win, and this is evident throughout the organization. Our culture of innovation and continuous improvement is well ingrained and by leveraging our unique growth strategies and culture of execution we have consistently driven incremental market share gains and robust earnings growth. Now we will move on to our growth strategies and how we leverage our strong competitive advantages to take market share and drive growth. First, the diversity of our business and fragmented customers means we need sophisticated processes, tools and analytics to identify the most attractive and profitable growth opportunities for our sales teams to pursue. Spinnaker is a collection of sales, service and marketing initiatives and processes that we used to drive sales growth and improve profitability. A key element of the program is to ensure that our sales teams are focused on winning new potential customers and driving cross-selling within existing accounts. In addition to generating leads for our sales teams through our various marketing activities, our topK program generates tailored and actionable investment alerts about specific sales opportunities especially in underpenetrated segments and hot segments in the market. We utilize our own proprietary databases and external data sources, combined with very sophisticated data analytics to generate these topK investment alerts, which are then dynamically qualified, prioritized and fed into our CRM for our sales teams to act on. We also use Spinnaker data analytics to identify customer sites in which we have low cross-selling penetration, and then use our contacts and references to develop leads for other product categories which have proven to be very effective. As part of our continuous improvement process, we periodically launch a new wave of Spinnaker that builds on the previous waves and initiatives. We are currently on the sixth wave of Spinnaker that encompasses a range of initiatives to further expand our digital capabilities and enhance our customer experience. This wave is focused on implementing additional digitalization and an expanded big data analytics effort for our lead generation and sales force guidance programs. These initiatives also provide our customers new insights to their installed base and service certifications while improving their experience with advanced platforms, digital sales rooms, the ability to engage with technical application consultants in chat and online meetings, and expanded customer feedback loops to improve the customer experience and make it easier to do business with us. Another important driver for our long-term growth is to accelerate the growth of our service business. As a reminder, service represents approximately 25% of our total sales and is a key part of our solutions offering, and is a very important competitive advantage as we support our customers' ability to maintain uptime, to improve productivity and comply with regulatory requirements. We aim to grow our service business faster than the company average over the medium term, and we are making dedicated investments in field technicians, in telesales and data analytics resources to support these growth targets. Our largest opportunity to grow our service business is servicing a greater proportion of our installed base. Today, we have penetrated about 1/3 of a $3 billion total market opportunity within our installed base. And given the vast amount of data we possess about it, like when the instrument was sold, who is using it, in what application it is being used, we can generate targeted sales campaigns to service them specifically tailored to their needs based on our data. Our presence in China and other emerging markets is another important growth opportunity. We have a strong local presence in China, which represents approximately 16% of our total sales. And we design and manufacture products for the local Chinese market. We are also well aligned with the central government's strategic goals of enhancing sales efficiency in key industries such as biopharma, semiconductors and many others. China is also an important part of our global supply chain, representing approximately 30% of our global manufacturing. However, we also continue to increase our global manufacturing flexibility with increased redundancy in different countries. We are also alert to potential tariffs. And while the magnitude and specifics remain unknown, we will strive to mitigate potential costs similar to our past approaches and leveraging our global footprint. As a reference, we currently export less than $100 million from China to the United States. Additionally, our sales in other emerging markets are significant and comparable to the size of our operations in China. We have a direct sales and service network across Southeast Asia, Eastern Europe and Central and South America. These are key competitive advantages that allow us to seize the promising long-term growth and prospects these regions represent. Underpinning our growth drivers is our technology leadership and our commitment to continuously enhance our industry-leading product offering. We are constantly coming out to market with new products and accelerated our rate of innovation over the past few years and introduced a new corporate program called Jetstream to enhance our innovation process. Our solutions generate new insights, help improve our customers' workflows, make their results more precise and reliable, make the instruments easier to use for less experienced scientists and support our customers' digitalization needs throughout the entire workflow. New products also helped stimulate replacement cycles, support market share gains and enhance our value proposition that supports our pricing. On this slide, you will see a handful of examples of recent innovations across our lab and industrial portfolio, and there are many more that we have launched that we have not included on this slide. We continue to see increased demand for automation and digitalization, and we will have additional product launches this year and directly -- that directly address our customers' needs in these areas. And while no one product launch is material to our results overall, given the significant diversity in our businesses combined, they are powerful contributor to our market share and margin expansion strategy. And while we are fundamentally focused on organic sales growth, we will also continue to look at inorganic growth opportunities through small- and medium-sized bolt-on acquisitions that can help expand our technology leadership, product offering and channel reach. We are typically looking to acquire businesses and technologies that are a good complement to our existing product offering, benefit from our global supply chain and manufacturing capabilities and can leverage our direct sales force. Now let's turn to our margin expansion initiatives where we also have a great track record. We remain confident in our ability to expand our operating margins by over 100 basis points per year. The main driver of margin expansion is organic sales growth which we target at 6% or better on average over the medium term. Our global pricing, SternDrive and Blue Ocean programs are also important drivers and enablers of margin expansion, while business mix is also a tailwind as faster-growing businesses have higher margins. As previously mentioned, we have accelerated our pace of innovation that further enhances our value proposition which is fundamental to our pricing program. We are also very focused on driving productivity and continuous improvement throughout the organization, helping fund our growth initiatives and driving margin expansion. SternDrive is our corporate program to drive productivity and cost reduction across our manufacturing organizations. We recently launched our third wave of SternDrive which includes new initiatives targeted at reducing material cost and improving shop floor and back office productivity. Our value engineering efforts have helped optimize our existing product platforms and we continue to look to enhance the cost of our purchase components and drive reductions in our material costs. We are also looking to implement semi-automated and low-cost automation solutions like [ cobots ] in our production facilities to reduce our manufacturing cost and increase quality. Stern Drive also leverages our digital capabilities, and benefits from our advanced analytical capabilities to diagnose areas for improvement. I remain very confident that our growth initiatives and operational excellence programs I have shared with you today will continue to help us to build on our excellent long-term track record of strong financial performance. While industry growth over the last 2 years has been below average, we believe our markets are well on track to return to more normalized growth as we progress through 2025. We moved very quickly in 2023 to adapt to the reduced level of market demand to protect our profitability. And over the past 2 years, we have also focused on sustaining dedicated investments to drive further future growth, including product innovation and service investments. We believe our balanced approach to protecting profitability and investing for the future will deliver tangible results going forward as our markets show gradual recovery over the coming year. So let me summarize the key points from my presentation today. First, we have a significant competitive advantage, including a very strong product portfolio, highly sophisticated go-to-market strategies and excellent service organization and a highly collaborative global team. Our culture of innovation, collaboration, agility and continuous improvement makes a tremendous difference and is a key competitive differentiator. Secondly, our team is squarely focused on driving growth. We continue to invest to support our innovation initiatives, growing our service business enhancing our best-in-class corporate programs like Spinnaker to drive growth and capture market share and also SternDrive to manage our costs effectively. And lastly, we remain fully confident delivering on our medium-term over-the-cycle financial targets. This includes 6% or better sales growth, driving over 100 basis points of margin expansion. We believe we have an excellent cash flow story and continue to aim to convert approximately 100% of our net income into free cash flow and return this to investors through our share repurchase program contributing to mid-teens level of EPS growth. Now that concludes my comments, and thanks, everyone, for joining us today.

Perfect. Thank you, Patrick.

So I figured maybe just given your guys' portfolio exposures and some of the equipment exposures there. First question, just on budget flush trends. I think that's a common theme that we've been hearing from some of your peers in the last few days. So I appreciate we'll get full numbers in a few weeks here. But qualitatively, any comments on if you guys saw a budget flush throughout 4Q?

Yes. Look, as you rightfully said, we will update you, of course, on Q4 in a couple of weeks, so I will not comment on budget flush today. But having said that, if you look back also what we said in Q3, actually, we saw a very -- pretty strong Q3. We saw positive growth. We saw especially strong results in Europe and also in our businesses with analytical instrument and process analytics. So I think we are quite happy with what we have seen in terms of first good signs of growth. We also have seen China coming back to growth. Europe was pretty strong. So as I said also in my notes, going forward for 2025, our guidance really reflects that the market conditions will continue to improve throughout the year. And we will give you a closer update on the budget [ flush ] that are right -- in our earnings call.

Yes. Maybe digging into that last point on the recovery from an end market, can you unpack that for us a little bit as we look throughout 2025. Should we expect this to be a more linear recovery? Should it be more hockey sticks? I have a follow-up question on 1Q and some logistics. But maybe just from an end market perspective, walk us through the assumptions there.

Yes. So if you kind of go back to our previous guidance, we certainly expected market conditions to gradually improve. If you kind of look at our sequential performance quarter-to-quarter, in 2024, between Q1, Q2 and Q3, you saw that. That was our guidance for Q4, and that's kind of how we expected the trend to be. So when you think about 2025, we expect the second half to be better than the first half. And then when we think about that then by -- you say end market, but maybe a better way for us to frame it is by our divisions. Like our laboratory division is the one area that we have a little bit more confidence in. If you look at our third quarter results, as Patrick was kind of mentioning, like we grew 5% in lab business in the third quarter. And then when we kind of like unpack that number, you saw very strong growth in analytical instruments. You saw very strong growth in process analytics and generally broad growth throughout the portfolio. And so that kind of gives us some more. That was one of the things that gave us a little bit more confidence for our guidance for next year. So on a reported basis, it would be like more low to mid-single digit, but we have this whole shipping delay topic that you mentioned, and I think we'll talk about in a second here. But if you exclude the shipping delay topic, that we expect that business to grow more mid- to high single digit next year. On the other hand, our industrial business, we feel like is a little bit more exposed to some of the topics in China at the moment. And just the more -- I think we're less dependent on the economy than we were, but we're still -- we still have an element of that. And so if you kind of like look at that business, we're a little bit more cautious. We're looking at a little bit more like low single digit on the core industrial side, as well as low single digit on the product inspection side.

Then my follow-up just related to this logistics issue. If we look back at JPMorgan last year, I think that dominated a lot of the airtime, hopefully, this is kind of the last quarter that we're talking about it here. But walk us through, obviously, that becomes a headwind to growth and margins this quarter, as you guys explained. So walk us through some of the math there on how we should see that impacting both top line and margins in 1Q. And then maybe if we just exclude that, again, the cadence from like 1Q into 2Q kind of like you spoke about there.

Yes. So I'll start with like maybe the full year, and then I'll kind of talk a little bit about the first quarter. So the full year, it's a 1.5% headwind to sales. So if you look at our sales growth of 3%, it would be 4.5%, excluding the shipping delay. If you look at our operating margins, it's about a 60 to 70 basis point headwind to our full year operating margins. And then to our EPS guidance, it's about a 4% headwind to our full year EPS guidance. So it would be 8% to 9% in terms of what we provided in on a full year basis, but it's all in Q1. And I think -- and so now if we kind of like go back to my previous comments about the first half of the year, being a little bit lower than the second half of the year in terms of growth. So take that 4.5%, make your own assumptions for second half versus first half. We'll provide a guidance update on Q1 in a few weeks. But once you do that, then in Q1, you have to subtract 6% in terms of the impact of the headwind for Q1 growth. And then in terms of operating margin, it's about a 250 to 300 basis point headwind to the operating margin. And then for EPS, it's high teens headwind for EPS growth in the first quarter. But then once we get past Q1, we'll be into more normalized -- we won't have this topic and we'll be into more normalized growth expectations.

Great. That's helpful. Maybe just on pricing. So your guidance assumes 2% pricing contribution this year. Can you walk us through your pricing power across various products throughout the portfolio, and kind of what gives you that resiliency and confidence that you're going to hit 2% pricing contribution in '25?

Yes. So we're 2% in the third quarter and year-to-date Q2. We feel good about that for next year. That's a number that we're very comfortable with kind of in that pre-COVID kind of range as well, too. I think one of the things we've been talking about, though, like when you think about pricing, one of the things that's really neat about is, in the end, it's realizing the benefits of your value proposition. And I feel like, as Patrick has talked about a lot, we've really accelerated investments in innovation and through that, we've enhanced our value proposition. And then I think the other thing is, is that the markets have been moving a little bit in our favor. As the markets move towards automated solutions and more digitalization, they play to the strength of our portfolio. So our value proposition has also been enhanced as well, too. So we kind of go into '25 feeling good about our ability to realize price increases. Our ability generally is broad-based throughout the portfolio. We tend to do -- in a typical year, we tend to do maybe a little bit better on the laboratory side of the portfolio. But generally, our results are very broad-based, by product and also typically by geography.

Great. And then just talking about the equipment and instrumentation exposure here. Obviously, spending has been soft from a CapEx budget standpoint throughout 2024. So can you spend a minute talking about if you've seen any green shoots in equipment and instrumentation spending recently? And then what are you really assuming for that part of your portfolio in terms of growth in 2025?

So yes, the green shoots we have been seeing, and I'm referring here again to Q3 is we have seen the strong pickup in analytical instrumentation and also process analytics, which first and foremost, is driven, of course, by our innovation and bringing that to the market and the acceptance of the customer really taking up this innovation. We also have seen the pharma business coming back to growth. We have seen Europe pretty strong in Q3 as well. And I think these, what we would call, green shoots actually give us a lot of confidence that we are #1, very well positioned with our product portfolio, that we have the right go-to-market strategy to capture these opportunities. And it will also continue the momentum into 2025. I mean what we are hearing from our customers is really that they are now, that we have 2 years of, I would say, reduced replacement business. Remember about 80% of our business is typically more like replacement business when it comes to instrumentation. So that had been slow over the last 2 years, so we are also pushing a bit of replacement cycle ahead of us.

That's helpful. Maybe shifting more towards your long-term outlook. Your LRP assumes 6% local currency growth. Just given how volatile and kind of dynamic the last few years have been, can you talk about how are you still thinking about that 6% long-term growth rate? Is that still achievable? And really, what gives you the confidence to be able to hit that guide?